Andrea Franson
Overview
Explore the profile of Andrea Franson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gajjar A, Mahajan A, Bale T, Bowers D, Canan L, Chi S, et al.
J Natl Compr Canc Netw
. 2025 Mar;
23(3):113-130.
PMID: 40073837
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in...
2.
Venneti S, Kawakibi A, Ji S, Waszak S, Sweha S, Mota M, et al.
Cancer Discov
. 2025 Mar;
15(3):657.
PMID: 40025951
No abstract available.
3.
Erez N, Furth N, Fedyuk V, Wadden J, Aittaleb R, Adam T, et al.
Cell Rep Med
. 2025 Jan;
6(1):101918.
PMID: 39809263
The analysis of cell-free tumor DNA (ctDNA) and proteins in the blood of patients with cancer potentiates a new generation of non-invasive diagnostic approaches. However, confident detection of tumor-originating markers...
4.
Vo J, Franson A, Waszak S, Wu Y, Becker N, Chinnaiyan A, et al.
Acta Neuropathol Commun
. 2024 Dec;
12(1):195.
PMID: 39707575
We identified a rare heterozygous germline loss-of-function variant in the tumor necrosis factor receptor-associated factor 2 (TRAF2) in a young adult patient diagnosed with medulloblastoma. This variant is located within...
5.
Hogarty M, Ziegler D, Franson A, Chi Y, Tsao-Wei D, Liu K, et al.
Br J Cancer
. 2024 Jan;
130(5):788-797.
PMID: 38200233
Background: MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to determine the maximum tolerated dose (MTD) of DFMO, an Odc inhibitor,...
6.
Mueller S, Kline C, Franson A, van der Lugt J, Prados M, Waszak S, et al.
Neuro Oncol
. 2023 Dec;
26(Supplement_2):S125-S135.
PMID: 38124481
Background Diffuse midline glioma (DMG) is a devastating pediatric brain tumor unresponsive to hundreds of clinical trials. Approximately 80% of DMGs harbor H3K27M oncohistones, which reprogram the epigenome to increase...
7.
Patel J, Aittaleb R, Doherty R, Gera A, Lau B, Messinger D, et al.
Neuro Oncol
. 2023 Dec;
26(Supplement_2):S101-S109.
PMID: 38096156
Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the...
8.
Erez N, Furth N, Fedyuk V, Wadden J, Aittaleb R, Schwark K, et al.
bioRxiv
. 2023 Dec;
PMID: 38045418
The analysis of cell-free tumor DNA (ctDNA) and proteins in the blood of cancer patients potentiates a new generation of non-invasive diagnostics and treatment monitoring approaches. However, confident detection of...
9.
Koschmann C, Al-Holou W, Alonso M, Anastas J, Bandopadhayay P, Barron T, et al.
Cancer Cell
. 2023 Dec;
42(1):1-5.
PMID: 38039965
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include...
10.
Venneti S, Kawakibi A, Ji S, Waszak S, Sweha S, Mota M, et al.
Cancer Discov
. 2023 Aug;
13(11):2370-2393.
PMID: 37584601
Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in...